Health and Healthcare
Neothetics Posts Solid Win on Patent Approval
Published:
Last Updated:
Neothetics Inc. (NASDAQ: NEOT) saw its stock hit a multiyear high on Wednesday after the firm announced a critical patent approval. The U.S. Patent and Trademark Office (USPTO) issued U.S. Patent Number 9,597,531, which deals with the specific methods of using Neothetic’s LIPO-202 and other agents for the reduction of fat accumulation.
The patent is expected to expire no earlier than the fourth quarter of 2031, extending the coverage time of the company’s intellectual property portfolio. This is the eighth issued U.S. patent directed to Neothetics’ lead product candidate LIPO-202, which is being evaluated for the reduction of submental fat.
LIPO-202 is an active ingredient of U.S. Food and Drug Administration (FDA)–approved inhaled products such as Serevent Diskus, Advair HFA and Advair Diskus. LIPO-202 has an extremely favorable safety profile, with little to no adverse post-treatment effects. The drug is being evaluated for the reduction of submental fat, commonly referred to as a double-chin.
Martha J. Demski, a member of Neothetics’ Operating Committee and board of directors, commented:
This patent further strengthens our comprehensive intellectual property portfolio protecting our lead clinical asset, LIPO-202.
For roughly the past year, the stock has stayed within the range of $1 to $2. The stock originally entered the market around $11 back in 2014, and the stock actually made gains for part of 2015 before falling off a cliff to the current price level.
Shares of Neothetics were trading up nearly 32% at $2.04 on Wednesday, with a consensus analyst price target of $3.00 and a 52-week trading range of $0.56 to $2.59.
Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
